Novartis AG (NVS)
After hours:
| Previous Close | 89.82 |
| Open | 88.85 |
| Bid | 85.35 x 800 |
| Ask | 90.60 x 800 |
| Day's Range | 88.68 - 90.13 |
| 52 Week Range | 74.09 - 94.26 |
| Volume | |
| Avg. Volume | 2,327,693 |
| Market Cap | 201.65B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 25.86 |
| EPS (TTM) | 3.48 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.33 (4.24%) |
| Ex-Dividend Date | Mar 08, 2022 |
| 1y Target Est | 100.75 |
- Simply Wall St.
Novartis AG's (VTX:NOVN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Novartis (VTX:NOVN) has had a great run on the share market with its stock up by a significant 5.6% over the last...
- Zacks
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
- GlobeNewswire
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious complement-mediated blood disorder New data evaluating the superiority of first-line (1L) Kisqali® plus endocrine therapy vs. combination chemotherapy in pre-menopausal patients with HR+/HER2- metastatic breast cancer with aggressive disease, including patients with visceral disease New analysis fr
